Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 13/20 | 0.40 |
| ▸ | MTHFD1 | P11586 | 9/20 | 0.40 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31535220 | 1.00 | MTHFD2 (0.40) | MTHFD2MTHFD1ERN1MAOAKDM4E | |
| SCHEMBL31535548 | 0.91 | MTHFD2 (0.39) | MTHFD2MTHFD1ERN1MAOAKDM4E | |
| SCHEMBL31535203 | 0.91 | MTHFD2 (0.40) | MTHFD2MTHFD1ERN1KDM4EALDH1A1 | |
| SCHEMBL31535507 | 0.90 | ERN1 (0.39) | MTHFD2MTHFD1ERN1KDM4EALDH1A1 | |
| SCHEMBL20209040 | 0.90 | ERN1 (0.41) | MTHFD2MTHFD1ERN1MAOAKDM4E | |
| SCHEMBL31535432 | 0.90 | ERN1 (0.39) | MTHFD2MTHFD1ERN1MAOAKDM4E | |
| SCHEMBL31535568 | 0.90 | ERN1 (0.39) | MTHFD2MTHFD1ERN1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL21354112 | 0.89 | ERN1 (0.41) | MTHFD2MTHFD1ERN1MAOAKDM4E | |
| SCHEMBL31535183 | 0.89 | ERN1 (0.38) | MTHFD2MTHFD1ERN1MAOAKDM4E | |
| SCHEMBL31535573 | 0.89 | ERN1 (0.38) | MTHFD2MTHFD1ERN1MAOAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | MTHFD2 4302/4885MTHFD1 4427/4885ERN1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.